WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H317193
CAS#: 117-37-3
Description: Anisindione (brand name Miradon) is a synthetic anticoagulant and an indanedione derivative. It prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K–mediated gamma-carboxylation of precursor proteins.
Hodoodo Cat#: H317193
Name: Anisindione
CAS#: 117-37-3
Chemical Formula: C16H12O3
Exact Mass: 252.08
Molecular Weight: 252.260
Elemental Analysis: C, 76.18; H, 4.79; O, 19.03
Synonym: Miradon; Anisin indandione; Unidone
IUPAC/Chemical Name: 2-(4-methoxyphenyl)indene-1,3-dione
InChi Key: XRCFXMGQEVUZFC-UHFFFAOYSA-N
InChi Code: InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3
SMILES Code: COC1=CC=C(C=C1)C2C(=O)C3=CC=CC=C3C2=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 252.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Grosset AB, Allen JE, Rodgers GM. Anticoagulation with anisindione in patients who are intolerant of warfarin. Am J Hematol. 1994 Jun;46(2):138-40. doi: 10.1002/ajh.2830460215. PMID: 8172181.
2: LANGE K, PERCHUK E, MAHL M, ENZINGER J, MOURATOFF G. Anisindione: a new anticoagulant with unusual properties. Am Heart J. 1958 Jan;55(1):73-9. doi: 10.1016/0002-8703(58)90257-6. PMID: 13520554.
3: CONNELL WF, MAYER GA. Evaluation of anticoagulant therapy with anisindione (miradon). Can Med Assoc J. 1959 May 15;80(10):785-90. PMID: 13652026; PMCID: PMC1831018.
4: Spyropoulos AC, Hayth KA, Jenkins P. Anticoagulation with anisindione in a patient with a warfarin-induced skin eruption. Pharmacotherapy. 2003 Apr;23(4):533-6. doi: 10.1592/phco.23.4.533.32130. PMID: 12680483.
5: Matschinske J, Salgado-Albarrán M, Sadegh S, Bongiovanni D, Baumbach J, Blumenthal DB. Individuating Possibly Repurposable Drugs and Drug Targets for COVID-19 Treatment Through Hypothesis-Driven Systems Medicine Using CoVex. Assay Drug Dev Technol. 2020 Nov/Dec;18(8):348-355. doi: 10.1089/adt.2020.1010. Epub 2020 Nov 6. PMID: 33164550; PMCID: PMC7703307.
6: BUZZI A, CARBAJAL B. [Clinical evaluation of the anticoagulant, anisindione]. Prensa Med Argent. 1961 Jun 23;48:1826-9. Spanish. PMID: 13875273.
7: FIELDER FG, HOFF EJ, BOLLES S, SIEGRIST JC. A study of the chronic toxicity of anisindione and phenylindanedione in dogs. Toxicol Appl Pharmacol. 1961 Jan;3:122-6. doi: 10.1016/0041-008x(61)90015-1. PMID: 13699368.
8: WILLIS PW 3rd, ZWEIFLER AJ. An evaluation of anisindione, a new and useful oral anticoagulant. Preliminary report. J Mich State Med Soc. 1962 Nov;61:1386-7. PMID: 14000965.
9: Freedman MD, Olatidoye AG. Clinically significant drug interactions with the oral anticoagulants. Drug Saf. 1994 May;10(5):381-94. doi: 10.2165/00002018-199410050-00003. PMID: 8037888.
10: Clark SL, Porter TF, West FG. Coumarin derivatives and breast-feeding. Obstet Gynecol. 2000 Jun;95(6 Pt 1):938-40. doi: 10.1016/s0029-7844(00)00809-7. PMID: 10831996.
11: PAUL HA, ARSCOTT PM, KOPPEL JL, OLWIN JH. Clinical experience experience with the anticoagulant anisindione (miradon). Surg Gynecol Obstet. 1959 May;108(5):605-15. PMID: 13647217.
12: GIBELLI A, DELUTTEROTTI A. RICERCHE SULL'AZIONE ANTICOAGULANTE DI UN INDANDIONICO (ANISINDIONE) AD AZIONE PROLUNGATA [RESEARCH ON THE ANTICOAGULANT ACTION OF AN INDANDIONE DERIVATIVE (ANISINDIONE) WITH PROLONGED ACTION]. Rass Int Clin Ter. 1964 Jan 15;44:1-8. Italian. PMID: 14126507.
13: BALLERINI G, LA PAGLIA S. Prime ricerche cliniche su di un nuovo anticoagulante della serie indandionica: l'anisindione [Preliminary clinical investigations on a new indandione type anticoagulant: anisindione]. Prog Med (Napoli). 1959 Jan 31;15(2):46-8. Italian. PMID: 13658270.
14: KELLAWAY G. Clinical evaluation of miradon. Br Med J. 1958 Oct 11;2(5101):889-91. doi: 10.1136/bmj.2.5101.889. PMID: 13572936; PMCID: PMC2026790.
15: BLAUSTEIN A. A preliminary report on the clinical use of a new anticoagulant (miradon). N Y State J Med. 1958 Mar 1;58(5):701-2. PMID: 13517546.
16: Murthy AR, Wyrick SD, Hall IH. Hypolipidemic activity of indan-1,3-dione derivatives in rodents. J Med Chem. 1985 Nov;28(11):1591-6. doi: 10.1021/jm00149a008. PMID: 4067989.
